Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gentlemen Start Your engines!!!!! .84 and moving to Dollarland!
In Fairness judging by Mr Poss's performance he seems to be running this business with good intentions. also the 1.5 million a quarter is still based on 25% capacity of the 28000 foot facility and doesn't include LSU or California. we don't know what he's intending to do with the 150 million shares if he dumps them on the market he's diluting but he may be using them to purchase other Grow Ups or to raise "SOME" capital. I'm not so quick to think MR.POSS is Just diluting the stock by his past track record. Just my opinion.
I took notice of this line in the filings for the shareholder meeting.
"To transact such other business as may properly come before the Meeting "
That can be defined as purchase of additional businesses. Maybe or maybe not just saying. That could be the reason for increase in shares. Glta
This is just my opinion I am no way and giving advice. I'm not a financial expert. But from what I see 250 million shares is not a lot and adding a 150mil shares to it is still not that much. A lot of these companies in this medical marijuana Market are in the billions of shares. now judging this by looking at what Mr. Poss track record so far I think in the short-term the price will drop but in the long term of 2018 the price will rise even with the increase of shares. With all the expansion he's going to need some working capital but with that expansion means more income. Just my opinion Glta
I would be the 1st to high five you if that happened but 7000% in 2018? That would be about $28.00 pps based on ($0.40) at ($0.60) $42.00 PPS. GBLX will do VERY WELL But I think about 2-5$ more realistic.
4 to 7 $ would be awesome I was being conservative in my prediction. but I can definitely see your evaluation coming. GLTA
My opinion $2.00 by end 2018.
Wow this is some RUN!
I kind of feel the same way about "reload 25-30" except There may not be enough time with three weeks away from California going recreational, we could hear a few different breaking news in those next couple of weeks I wouldn't want to be caught without my shares.
And the real big Mega news as far as I'm concerned will be a surprise announcement from the federal government to reschedule medical marijuana. Don't get caught without you shares on that news.
I posted this Oct 3 about Texas & Parttimetrader Posted about Cali "Los Coyotes Band Tribe"
"Texas CBD Licenses Awarded Conditionally to Top Three Scorers"
Texas, which signed its Texas Compassionate Use Act on June 1, 2015, has awarded three conditional licenses to cultivate, process and dispense low-THC cannabis to intractable epilepsy patients. Of 43 applicants, one was disqualified for unspecified reasons. Each of the remaining 42 were scored by a review panel with eight Department of Public Safety employees who scored the applications across six categories, including Security (20%), Accountability (20%), Financial Responsibility (10%), Technical and Technological Ability (20%), Infrastructure (20%) and Cover Letter (10%).
The highest ranked applicants included Cansortium Texas, Compassionate Cultivation and Surterra Texas, and they will now undergo onsite inspections. The bill requires that final licensing is complete by September 1st. The state provided a ranking of each of the 42 applicants by score as well as a breakdown of the components contributing to their scores:
Cansortium Texas 93.62333
Compassionate Cultivation 92.49333
Surterra Texas 89.67667
Arete Holistics 88.83667
GB Sciences 85.91667...........(Holy $hit LOL getting close)
Col. Care Texas 85.605
VMG 83.52333
Mercury Copper Farms 80.71167
Lone Star Compassion Center 80.50333
Paradigm Pharm 80.055 L
ionnac 79.86
GTGC 79.13833
GreenWell 78.88167
Big Star 78.22167
Texas Wellness 78.20833
Alamo CBD 76.96833
Texas Compassionate Care 75.7
CannOrganics 74.52
Auxilium Farms 74.23667
Medicus 72.41 J and L Plants 72.205
Texas Has Compassion 72.16333
Texas Compassionate Enterprise 71.98
Bayou City 70.27167
Aviva 67.31833
Craft Harvest 63.725
Sensi Enterprises 63.26667
Epilepsy CBD 61.34
Texas Re-Leaf 57.38833
RXTX 55.93667
Travis Pharmaceutical 53.37167
Navarro Growers 52.50833
Bocanna 51.98833
Blue Bonnet 51.46667
Bootlegger 50.29167
Dallas Progressive Health 50.025
Texas Cannabis 49.98667
PowerBerman 43.95667
SLAMMA Solutions 33.855
Cannliv 22.225
ESG Epsilon 20.92
Lime Star Leaf 16.225
Surterra is a name that may be familiar to readers, as it is one of the seven license holders in Florida. Two publicly-traded companies, GB Sciences (OTC: GBLX) and Indoor Harvest (OTC: INQD), which is in the process of merging with Alamo CBD, were among the applicants, with GB Sciences ranking 5th and Alamo CBD 16th. Surprisingly, Columbia Care, which is one of the largest operators of vertically integrated medical cannabis dispensaries in the country, failed to win a license, scoring 6th.
https://www.newcannabisventures.com/texas-cbd-licenses-awarded-conditionally-to-top-three-scorers/
The news I'm expecting to hear in the next 30 to 45 days "hopefully"
1) Phase 2 completed in Vegas.
2) LSU (Temporary) grow facility is completed.
3) we get our California grow license.
4) we get our Texas grow license.
I just tried the link on my Android Samsung phone and it works. Try a different web browser on your phone. Firefox, Google Chrome Etc. Unless your crapple my sympathies. Jk jk
A quick read online shows indoor plants generally do 5 to 10 oz per plant. GB science produced 24 oz. Outdoor plants can produce up to 3 to 5 pounds. Nothing Like the Sun.
I'm sitting here thinking about the last PR about growing 1.5 lb per plant. That's actually really impressive. They might have some method that they could patent and sell 2 other growing facilities. Just a thought.
There must be some big news about to break.
BadKarmaKyle, Shaark I don't disagree with either of you. I think Mr Poss is doing a great job and "in my opinion" I feel we will be above .50 by summer 2018. I was just posting that Ellins is selling and selling a lot and does not have to inform anyone now thats he is not part of GBLX. The only thing that concerns me, is he MUST KNOW what the next 12 months goals are. So why sell now?
I posted this 8/08/17. Now that Ellins is not part of the company he does NOT have to disclose when he sells. So He was unloading for a while he must still be.
""I noticed Craig Ellins Owned 2,147,278 Shares of GB Sciences on (04/24/17)
Then retires (05/08/17)
Now Form 4 shows he owns as of (08/04/17) 5,761,000 shares.
He must have been given about 2.5 mil shares for retirement?
He has been unloading since (03-02-17).
https://www.sec.gov/Archives/edgar/data/1165320/000093979817000067/xslF345X03/primary_doc.xml
https://www.sec.gov/cgi-bin/own-disp?action=getowner&CIK=0001366150 ""
Legal Cannabis Market Continues to Mature.
A report published by Arcview Market Research, indicates that the legal cannabis industry will grow at 22% CAGR in 2017, as the eight states that voted to open or expand their cannabis markets on Election Day in November 2016, will work to implement new businesses, programs and products. According to the report the industry accelerated at a remarkable pace in 2016. North American consumers spent $6.7 billion on legal cannabis products, which represents an increase of 34% from 2015. The data forecasts the legal cannabis industry will grow robust 27% CAGR to $22.6 billion by 2021. Global Payout, Inc. (OTC: GOHE), Greengro Technologies, Inc. (OTC: GRNH), Cannabis Science, Inc. (OTC: CBIS), Surna, Inc. (OTC: SRNA), GB Sciences, Inc. (OTC: GBLX)
A major issue the legal cannabis market has to deal with is raising money. Because of discrepancy between states and federal laws, banks still often are not willing to open checking accounts and do not lend money for cannabis business. A report by paymentssource.com indicates that a shop that handles its payments electronically is less able to commit tax fraud and less likely to be a target of theft. As result, some concerns that financial institutions have may be dealt with. "You're starting to see a tendency, a healthy capitalistic tendency, for banks and credit unions that know they are missing out on or losing money by not working with marijuana businesses," said Serge Chistov, an investor and financial consultant for Honest Marijuana, a recreational grow house in Denver, Colorado.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. On October 23, 2017, the company announced that it projects sales of $500,000 in October and continued sales of at least $500,000 per month over the next three months. GB Sciences recorded unaudited sales of approximately $320,000 in the three months ended 9/30/17. The company is operating at 200 grow lights, which is only 30% of its expected final capacity after build out is completed. After the final build out, cultivation revenues will continue to increase with a target flower capacity of $18Million annually. The company is expected to open its production facility in late November or early December of 2017. This operating unit should generate additional significant free cash flow from oil over 2018 at a steadily accelerating pace.
https://www.prnewswire.com/news-releases/legal-cannabis-market-continues-to-mature-659060073.html
ROBERT MOODY SCHEDULE 13G AMEND 1
https://www.sec.gov/Archives/edgar/data/1165320/000093979817000088/0000939798-17-000088-index.htm
GB Sciences is Happy
Mr. Kevin Kuethe has been appointed COO of GB Sciences. The company is happy, the plants are happy, the customers are happy, and the shareholders should definitely be happy.
November 13, 2017 05:30 ET | Source: GB Sciences, Inc.
photo-release
Image from an interview with GB Sciences COO Kevin Kuethe
Las Vegas, NV, Nov. 13, 2017 (GLOBE NEWSWIRE) -- GB Sciences, Inc. (OTCQB: GBLX) announces that it has met the October gross revenue projection of $500K from the sale of premium flower. Gross sales projections for the month of November are also trending in this direction.
CLICK HERE TO WATCH VIDEO
With reported gross sales of only $320K in the last financial quarter, how did this drastic turnaround occur? This question was posed to newly appointed COO Kevin Kuethe.
"Any time you grow at scale, more than 100 lights, it takes a few harvest cycles to 'fine tune' the operation. And fine tuning our custom concentrated nutrient blends is a key element in the process. After all, it is the nutrition that keeps the plants healthy, and each strain eats a little different blend of nutrients to maximize the genetic potential of each of our strains. Now the entire process is dialed in and we are operating our precision controlled growing environments for maximum consistency, quality and yield."
The GB Sciences cultivation facility has 180 active flower lights for plant cultivation. With an industry standard yield of approximately one and one half (1.5) pounds yield per flower light (of cured, untrimmed flower), and the current market rates per gram of cannabis in the Nevada market, it seems impossible to get this kind of recurring revenue from a cultivation facility of this size.
"Improbable, yes… but impossible, no," said Mr. Kuethe. "Our growing techniques have an intangible that we like to call: happiness. And by happiness, I'm referring to a feeling, a vibe, an intangible that we are all on the same mission and in the same direction to do better, to be better and you can see it in the way we work, and you can definitely see it in our plants. They are large, healthy, and produce consistently high yields. We do this by using state-of-the-art modern growing techniques to create and control the growing environment…yes. But inside that environment, our growers bring a deep experience and understanding of the plant, along with a truly happy vibe. That's how we get basically double the industry average yield. The plants pick up on that vibe and it shows all the way throughout their lives. And the numbers speak for themselves. We cultivate happy plants, and the happiness spreads to the dispensaries all the way down to the consumer. Call it crazy, but it's real. Our entire ecosystem is happy… like a room without a roof."
GB Sciences, Inc.
GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to:http://gbsciences.com
https://globenewswire.com/news-release/2017/11/13/1184975/0/en/GB-Sciences-is-Happy.html
I expect to see an increase in income but also expect to see a lot of expenses due to build outs like LSU and Phase 2 in Vegas. But once they're complete the income will rise greatly. Looking forward to it.
GB SCIENCES, INC. PARTNERS WITH CURA CANNABIS SOLUTIONS AND ENTERS THE LUCRATIVE CANNABIS OIL MARKET IN NEVADA This production agreement guarantees GB Sciences a set royalty on every gram produced and sold. It is projected to add significant net profits to the bottom lines of both partners in 2018
October 30, 2017 05:30 ET | Source: GB Sciences, Inc.
Las Vegas, NV, October 30, 2017/GLOBE Newswire, Oct. 30, 2017 (GLOBE NEWSWIRE) -- GB Sciences, Inc. (OTCQB: GBLX) and Cura Cannabis Solutions (Cura) have executed a production agreement to produce high quality cannabis oils and related products utilizing the GB Sciences production license operated by the GB Sciences’ Cultivation Labs™.
Presently the largest cannabis oil company in Oregon with operations up and running in California and now Nevada, Cura is the leading provider of premium cannabis oil and hemp oil to the legal domestic and international markets, and is widely respected in the industry for the quality of its products. The company is known for its Select Oil and Select CBD brands, offering a variety of products that reach cannabis consumers of all experience levels.
Cura projects oil production and sales in Nevada to be approximately 250,000 grams of oil per month at the outset, growing to approximately 500,000 grams per month over the near term.
"Quality, scale, and deep domain expertise are three critical elements that factor into the success of our company -- and this relationship with GB reflects a collaboration between two businesses which are well-equipped for what's ahead in the regulated cannabis market," said Cura Cannabis Solutions CEO Nitin Khanna. "We look forward to working together to develop premium products for Nevada, and have big plans for the future alongside GB Sciences."
This production agreement guarantees GB Sciences a set royalty on every gram produced and sold under the agreement, an enterprise which will provide GB Sciences with a significant and growing monthly cash flow.
The arrangement with Cura also firmly establishes GB Sciences as a vertically integrated cannabis company, adding oil production to its proprietary tissue propagation, cultivation, and distribution capabilities. This is in keeping with the Company’s long-established expansion plans, which are proceeding successfully and on a timely basis
New retail brands are in the planning stage, which, when completed, will enable both Cura and GB to take full advantage of their enviable market positions. GB CEO John Poss said,“Together, we will become a formidable force in the Nevada cannabis market, and we have plans to expand our combined reach to many other states.”
About GB Sciences, Inc.
GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to:http://gbsciences.com
About Cura Cannabis Solutions
Cura, one of the largest cannabis brands in America, is on a mission to be the leading provider of cannabis in legal U.S. and international markets. Known as the maker of the Select Oil and Select CBD suite of products, and winner of Dope Magazine’s 2017 Best Concentrate Company Award, Cura’s mission is to provide patients and customers with the cleanest, most flavorful cannabis, with the safest delivery method available. Established in Portland, Oregon in 2015, Cura expanded into California and Nevada in 2017. Learn more about Cura Cannabis Solutions at: http://www.curacan.com ;
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
CORPORATE
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118, 1-866-721-0297
https://globenewswire.com/news-release/2017/10/30/1159769/0/en/GB-SCIENCES-INC-PARTNERS-WITH-CURA-CANNABIS-SOLUTIONS-AND-ENTERS-THE-LUCRATIVE-CANNABIS-OIL-MARKET-IN-NEVADA.html
Ms. Poss did mention to shaark on a phone call last week that he is interested in getting up listed to the NASDAQ. That will be real interesting he needs to get the price up to $4 a share to be considered.
Ooooook, if thats what you got from those articles go with that.
Their not the only MMJ producer in Louisiana. Their 1 of only 2.
http://m.wafb.com/wafb/db_330682/contentdetail.htm?contentguid=aKus2bQL
UF Researchers Begin Study On Marijuana As Opioid Alternative.
University of Florida Health doctors have begun a new study looking at the health effects of marijuana on people with HIV, including its potential as an alternative to addictive opioids.
The doctors will be monitoring the patients and their marijuana use. They will be exploring both negative and positive effects of using cannabis as medicine, said Dr. Robert Cook, the study’s lead investigator.
Many HIV patients take the drug to help with sleep, pain and stress, Cook said.
The study is scheduled to go for the next five years and is being paid for by a recently announced $3.2 million grant from the National Institute on Drug Abuse, he said. UF Health researchers applied for the grant twice before receiving it.
Marijuana is legal for people with HIV/AIDS in Florida. Other Southern states — Georgia, Kentucky, Mississippi and South Carolina — have medical marijuana laws, but they don’t include HIV/AIDS as a condition that would qualify for use of the drug.
The researchers will be studying patients only in Florida. They won’t be providing the marijuana, which must have already been obtained by the patient, and they won’t ask whether the patient got the marijuana illegally or through a prescription.
“Not many people have it with a prescription yet, so we will also be looking at if there is a difference between the prescription marijuana and what people get off the street,” Cook said.
On researching possible negatives, Cook said the worry is “about addiction and the stereotypical side effects.”
Side effects could be addiction, sleepiness, laziness and intoxication. These could cause problems for patients who have a job that involves driving or the use of machinery, Cook said.
Another reason Cook said he wanted to conduct the study is to see if there is an alternative to giving patients opioid pain killers. These can be especially addictive when prescribed, so many physicians are looking for alternative prescriptions for people who are HIV positive, he said.
The study will hopefully bring about more information that is not yet available to physicians about medical marijuana, Cook said.
https://www.wuft.org/news/2017/10/26/uf-researchers-begin-study-on-marijuana-as-opioid-alternative/
GB science is not selling anything to Louisiana they are building a facility there and growing it there. They will also be building a facility in California and Texas. I read in the previous article I posted they should be finished with the facility end of 2017 (I imagine they are talking about Phase 2 in Las Vegas). That's pretty close!
The Relationship Between Legal Cannabis and the Plant Factory Grows Lights Market.
NEW YORK, October 26, 2017/PRNewswire/
According to a data provided by Zion Market Research, the global plant factory grows lights market was valued USD 2.73 billionin 2016 and is expected to reach around USD 5.11 billion by 2022, at a CAGR of 11.01% for the forecast period from 2017 to 2022. Plant factories are considered to be the future of farming. New popular methods such as vertical farming and the growing implementation of urban agriculture are major factors in the future of this market, as interests and investments for plant factories and related technology is increasing. The report also indicates that North America is expected to be the highest growing segment in the plant factories and grow lights market. The emergence of vertical farms and the booming market for cannabis cultivation are driving demand to new highs in the North American region. Light Engine Design Corp. (OTC: TLED), Cannabis Wheaton Inc. (OTC: KWFLF), GB Sciences, Inc. (OTC: GBLX), mCig, Inc. (OTC: MCIG), Mountain High Acquisitions Corp. (OTC: MYHI).
The effects of the cannabis industry on the plant factory grows lights market will depend on the growth of the cannabis industry and success of legalization campaigns. In states like Californiafor example, analysts are projecting an increase in sales of Cannabis products for medical and recreational use. "California offers the perfect example of why it is so important to understand trends in consumer behavior. The state's legal (cannabis) industry is forecast to grow from $2.8 billion in 2017 to$5.6 billion in 2020. That spending will be increasingly directed at products and retailers who understand and serve the market's evolving tastes and preferences. The market is changing, and the most successful operators will be those who adapt most quickly to the change," said New Frontier Data CEO Giadha Aguirre De Carcer.
Light Engine Design Corp. (OTC: TLED) announced breaking news earlier today that, "a wholly-owned subsidiary of Light Engine Design Corp, is an industry pioneer specializing in the design of advanced light engines and fixtures for frequency-specific biological lighting industries. The Company is pleased to announce that it has achieved a breakthrough in spectrum design that is increasing crop yields and product quality in the indoor cultivation of legal cannabis and food products. This is significant given the importance of generating large amounts of high-quality food using environmentally sustainable practices.
The CEA and greenhouse markets are expected to expand significantly in conjunction with novel revolutionary advancements in lighting technology. "In an effort to serve an exponentially growing marketplace, we have diligently strategized to bring to market one of the most advanced indoor growth lighting systems available, thus bringing heightened efficiency and improved profitability to the legally growing cannabis industry, a market experiencing robust growth. Our technologies also have tremendous application in the food industry, which we believe will continue to experience strengthened demand, congruent to population growth." said Robert Manes, Tall Trees' Chief Executive Officer. At this time, the LED lighting sector is an intricate key to all indoor agricultural environments, particularly legal cannabis. U.S. legal retail cannabis sales were projected to rise more than five times between 2014 and 2018, from an estimated $2.2-$2.6 billion in 2014 to $7.4-8.2 billion in 2018, according to an article published by Marijuana Business Daily.
Tall Trees LED Company also announced the achievement of its client's recent 1st and 2nd placement among Arizona's 2017 ERRL Cup winners for the quality of their cannabis flower. A Tall Trees' licensed and registered grower achieved the results using lighting produced and currently available through the Company's retail and wholesale sales channels. Third-party test results were provided by C4 Laboratories, a well-respected Phoenix-based cannabis testing facility. C4 representatives commented that the THC levels ( > 32% total cannabinoids) that were detected were the 3rd highest to have been observed to date; the highest produced by solid-state lighting. To view test results in their entirety, visit:http://theerrlcup.com/cannabis-event-results/ andhttp://theerrlcup.com/errl-cup-winners-2017/ ;. The Tall Trees' grower goes by the moniker "Maxx Trees."
Until recently, light output in relation to power input (efficacy) in LED lighting has been insufficient to grow premium quality plants. Furthermore, the frequencies of light required for adequate nutrient delivery and control of a plant's other biological functions have previously been a major oversight in the LED lighting industry. However, the Tall Trees LED Company has responded to these inefficiencies in the cannabis sector. Tall Trees' CEO, Robert Manes states, "there are many compelling scientific and peer-reviewed articles beginning to define the benefits of spectrum (frequency) control for food production, and we intend to extend this research and development to control yield, aroma, flavor, and a multitude of targeted medicinal qualities in cannabis."
Tall Trees' horticultural products follow strict internal guidelines for Coverage, Color (spectrum) and Photon Density (CCPD). The Company's fixtures are designed to cover industry-standard grow trays, provide spectrum that emulates natural sunlight, (which is the best overall grow light) and delivers the photon demand required to satisfy all of a plant's photobiological needs. Tall Trees' technology utilizes the latest research in photobiology to tailor lighting output for optimum growth, aesthetics, chemical and nutritional content.
Cannabis Wheaton Inc. (OTC: KWFLF) is the first cannabis streaming company in the world. The company streams will include production from across Canadacoming from its partners comprised of licensed producers of cannabis (LP) and LP applicants. On October 17, 2017, the company and Beleave Inc. announced that CBW has provided an initial advance of $5,000,000 in non-dilutive debt financing by way of an instrument evidencing a debt obligation repayable in product equivalents. As previously announced, the proceeds of the D.O.P.E Note will be used by Beleave to fund the construction of an expansion facility, to be situated adjacent to Beleave's current facility outside of Hamilton, Ontario.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. Recently, the company projected sales of$500,000 in October and continued sales of at least$500,000 per month over the next three months. GB Sciences recorded unaudited sales of approximately $320,000 in the three months ended 9/30/17. The company is operating at 200 grow lights, which is only 30% of its expected final capacity after build out is completed. After the final build out, cultivation revenues will continue to increase with a target flower capacity of $18Millionannually. The company is expected to open its production facility in late November or early December of 2017. This operating unit should generate additional significant free cash flow from oil over 2018 at a steadily accelerating pace.
Mountain High Acquisitions Corp.(OTCQB: MYHI) is a turnkey, cutting-edge infrastructure provider to licensed cannabis growers, processors and producers in regulated markets. In addition to assisting in the design, permitting, development and operation of scalable infrastructure, MYHI helps licensed operators leverage scientific and technological innovations specifically geared to optimize the cultivation and processing of cannabis. Recently, the company announced that it has expanded its pilot program, which is focused on providing turnkey infrastructure solutions to licensed cannabis growers. Now, with the help of its strategic partner D9 Manufacturing, Inc. (D9), the program agenda has expanded to include the development of reliable Standard Operating Procedures (SOPs) that growers will be able to utilize to greatly reduce the risk of low yield or failed grows. To that end, D9 is focused on fine-tuning SOPs and best practices which will enable growers to cultivate with efficiency, achieve above-average yields, and produce a harvest that is visually rich, extremely fragrant, pleasantly palatable, and free of harmful chemicals.
mCig, Inc. (OTCQB: MCIG) is a diversified company servicing the legal cannabis, hemp and CBD markets via its lifestyle brands. mCig, Inc. is committed to being the leading distributor of technology, products, and services to fit the needs of a rapidly expanding industry. On October 5, 2017, the company announced that the company has signed an agreement to purchase land inKern County, California, expanding its asset base in preparation forCalifornia's January 1, 2018 "Green Rush." MCIG is expanding its business model to include cultivation, production, and distribution. The proposed initial build out in California will cover 50,000 square feet of greenhouse cultivation space that can produce 1,600 lbs and generate conservatively $2.4m a month in revenues.
https://www.prnewswire.com/news-releases/the-relationship-between-legal-cannabis-and-the-plant-factory-grows-lights-market-653333803.html
GB-Sciences Increased Sales 400% Since First Harvest.
LAS VEGAS, Oct. 23, 2017/PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) projects sales of$500,000 in October and continued sales of at least$500,000 per month over the next three months. GB Sciences recorded unaudited sales of approximately $320,000 in the three months ended 9/30/17.
The company is operating at 200 grow lights, which is only 30% of its expected final capacity after build out is completed. After the final build out, cultivation revenues will continue to increase with a target flower capacity of $18Million annually. The company is expected to open its production facility in late November or early December of 2017. This operating unit should generate additional significant free cash flow from oil over 2018 at a steadily accelerating pace.
GB Sciences' Cultivation Labs™ yielded a first harvest the last week in June 2017. Between July 1st and September 31, 2017 the initial crops or 'spins' were harvested and sold. These first crops were used to give valuable feedback on everything from nutrients, to irrigation, to environmental controls. These initial crops have led to producing a very high quality medical grade cannabis.
Throughout the third quarter, the propagation and cultivation systems continued to be refined and the quality of the cannabis flower improved. This improved flower quality has also improved the sales price per gram. In the month of October alone, premium flower sales have yielded $500K.
Las Vegas adult use sales for the first month of operation were twice those generated byColorado during their first month of adult use, and seven times that of Oregon andWashington. This high demand has produced a cannabis shortage in Nevada. All revenue projections are subject to fluctuations in the wholesale price of cannabis in the Nevadamarket.
GB Sciences is now beginning the packaging and distribution of pre-roll and premium flower products. This product will be sold as retail through dispensaries. The revenue story will now have a consistency that matches GB Sciences' verified seed-to-sale process.
"Ours is a strong revenue story and getting stronger," said John Poss, CEO, GB Sciences. "We've come a long way and are now the company to watch."
About GB Sciences, Inc.
GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to:http://gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
Contact Information
Corporate:
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297
View original content with multimedia:http://www.prnewswire.com/news-releases/gb-sciences-increased-sales-400-since-first-harvest-300540935.html
SOURCE GB Sciences, Inc.
http://markets.businessinsider.com/news/stocks/GB-Sciences-Increased-Sales-400-Since-First-Harvest-1005318485
Nice phone call Shaark, thanks for that info. Sounds like we are going to be a big player soon.
I agree, I just wish I had more available funds debating on selling some other stocks.
Kind of surprising with all the news coming out this year About GB science and the future expansions in the next few months it surprises me this is hovering above 52 week low. Wish I had extra cash I'd be buying it up now.
GB Sciences Obtains Exclusive Worldwide License on a Time-Released Cannabinoid Formulation for Neuropathic Pain
https://www.prnewswire.com/news-releases/gb-sciences-obtains-exclusive-worldwide-license-on-a-time-released-cannabinoid-formulation-for-neuropathic-pain-300537302.html
Posted on Facebook: GBSciences, Inc. 09/28/17 "Right now we are operating at about 30% capacity utilization rate for the cultivation in our Las Vegas facility. Once the Teco phase 2 construction is completed, we will have an output of a little more than triple what we are producing now."
I'm thinking the LSU contract deal is the biggest attraction to Big Pharmer. that's the key for them to buy us out.
I don't think anyone is paying attention to the patents right now because they will take years to become valuable. BUT I have been thinking if they reschedule MMJ from the feds someone in BIG Pharma my Purchase GB Sciences assets in furture. I do think GB is going to take off end of the year or beginning 2018. Glta
"GB Sciences Inc. Adds Provisional Nevada Recreational Cannabis License for Branded Recreational Products"
GB Sciences Will Bring Medical-Grade Cannabis to the Recreational Use Market by Introducing Cultivation Labs™ Branded Products
LAS VEGAS, July 10, 2017 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) has added its own medical-grade retail brand to its already strong portfolio, which includes granted-medical and provisional-recreational use Nevada cultivation licenses and patent-pending medical formulations.
The decision to sell to the recreational market through the addition of GB Sciences' own trusted-ingredient retail brands, strengthens the Company's vertically-integrated strategy of controlling product quality and purity from seed-to-sale. Premium flower and medical-grade oils for use in vape pens and tinctures will be sold under the Cultivation Labs banner.
On July 1st, Nevada joined Colorado, Oregon, Washington, and Alaska, to become the fifth state to legalize the use of recreational cannabis. Expectations ran high for the state given its international entertainment destination, Las Vegas. This city hosts forty-two million visitors annually – many of whom will take advantage of the new law. Dispensaries reported long lines with forty-five minute waits and extended hours. One such dispensary, ReLeaf, reported 1000 customers per day vs. a previous count of only 100-150 customers per day. The Nevada Dispensary Association reported three million in sales revenue for this four-day holiday weekend.
John Poss, CEO, GB Sciences, remarked: "The arrival of recreational sales in Nevada presents a unique and well-timed opportunity for GB Sciences. It will allow the Company to self-fund the research and development of our medical formulations, while building a globally trusted brand for recreational users. What better city than Las Vegas to show the world that the quality and purity of medical grade ingredients can and should be demanded in recreational products. We look forward to satisfying this demand for every visitor that comes to town."
About GB Sciences, Inc.
GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, medical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
http://www.kxxv.com/story/35845452/gb-sciences-inc-adds-provisional-nevada-recreational-cannabis-license-for-branded-recreational-products
"Texas CBD Licenses Awarded Conditionally to Top Three Scorers"
Texas, which signed its Texas Compassionate Use Act on June 1, 2015, has awarded three conditional licenses to cultivate, process and dispense low-THC cannabis to intractable epilepsy patients. Of 43 applicants, one was disqualified for unspecified reasons. Each of the remaining 42 were scored by a review panel with eight Department of Public Safety employees who scored the applications across six categories, including Security (20%), Accountability (20%), Financial Responsibility (10%), Technical and Technological Ability (20%), Infrastructure (20%) and Cover Letter (10%).
The highest ranked applicants included Cansortium Texas, Compassionate Cultivation and Surterra Texas, and they will now undergo onsite inspections. The bill requires that final licensing is complete by September 1st. The state provided a ranking of each of the 42 applicants by score as well as a breakdown of the components contributing to their scores:
Cansortium Texas 93.62333
Compassionate Cultivation 92.49333
Surterra Texas 89.67667
Arete Holistics 88.83667
GB Sciences 85.91667...........(Holy $hit LOL getting close)
Col. Care Texas 85.605
VMG 83.52333
Mercury Copper Farms 80.71167
Lone Star Compassion Center 80.50333
Paradigm Pharm 80.055 L
ionnac 79.86
GTGC 79.13833
GreenWell 78.88167
Big Star 78.22167
Texas Wellness 78.20833
Alamo CBD 76.96833
Texas Compassionate Care 75.7
CannOrganics 74.52
Auxilium Farms 74.23667
Medicus 72.41 J and L Plants 72.205
Texas Has Compassion 72.16333
Texas Compassionate Enterprise 71.98
Bayou City 70.27167
Aviva 67.31833
Craft Harvest 63.725
Sensi Enterprises 63.26667
Epilepsy CBD 61.34
Texas Re-Leaf 57.38833
RXTX 55.93667
Travis Pharmaceutical 53.37167
Navarro Growers 52.50833
Bocanna 51.98833
Blue Bonnet 51.46667
Bootlegger 50.29167
Dallas Progressive Health 50.025
Texas Cannabis 49.98667
PowerBerman 43.95667
SLAMMA Solutions 33.855
Cannliv 22.225
ESG Epsilon 20.92
Lime Star Leaf 16.225
Surterra is a name that may be familiar to readers, as it is one of the seven license holders in Florida. Two publicly-traded companies, GB Sciences (OTC: GBLX) and Indoor Harvest (OTC: INQD), which is in the process of merging with Alamo CBD, were among the applicants, with GB Sciences ranking 5th and Alamo CBD 16th. Surprisingly, Columbia Care, which is one of the largest operators of vertically integrated medical cannabis dispensaries in the country, failed to win a license, scoring 6th.
https://www.newcannabisventures.com/texas-cbd-licenses-awarded-conditionally-to-top-three-scorers/
GB Sciences "expand into a multi-state footprint with licenses in California, Texas, and perhaps Louisiana and Florida."
The cannabis industry is expected to surpass $50 billion by 2026, according to Cowen & Co., driven by medical and recreational legalization efforts. There are many companies operating in the space – ranging from cultivators to biopharmaceutical companies – but investors should consider seeking out those with advanced operations and a diversified footprint in order to mitigate risk and ensure optimal long-term risk-adjusted returns.
In this article, we will take a look at GB Sciences Inc. (OTCQB: GBLX) and its progress in developing its intellectual property portfolio and paving the way toward success.
Developing an IP Portfolio
GB Sciences has been diligently building an extensive portfolio of intellectual property (“IP”) as a starting point for its clinical programs since mid-last year. In July 2016, the company formed Growblox Life Sciences LLC as a wholly-owned subsidiary to pursue development of IP related to unique cannabis-based medical compounds in conjunction with Fenwick & West, a Silicon Valley-based law firm focused on life sciences and high tech companies.
Growblox Sciences began by acquiring IP from Makai Biotechnology LLC back in December covering therapeutic methods for the treatment of cardiac hypertrophy and associated pathologies through regulation of the cannabinoid receptor TRPV1. The move was significant given that cardiovascular diseases account for more than 17.3 million deaths per year, which has spurred a growing need for new drugs that reverse cardiac hypertrophy and failure.
In February, the company filed a second series of patent applications covering cannabinoid-containing complex mixtures (“CCCM”) capable of preventing and treating a spectrum of inflammatory disorders. The application specifically focuses on using CCCMs to disrupt the signaling pathways in certain immune cells that lead to the initiation and maintenance of inflammatory responses in the human body.
The company’s Chief Science Officer, Dr. Andrea Small-Howard, has 15 years of experience studying cannabinoids and the endocannabinoid system, immunology, and cancer treatments, as well as executive experience in the biopharmaceutical industry where she supervised R&D, manufacturing, and quality control. She’s supported by three universities and a contract research organization (CRO) with experience conducting clinical trials.
Becoming a Licensed Cultivator
GB Sciences recently began cultivating medical marijuana in Nevada and will harvest it plants in April. The Company currently is pursuing additional licenses in California, Texas, and Louisiana– as a means to finance its biopharmaceutical programs to provide easy access to source materials needed to conduct clinical trials. The company anticipates achieving a $12 million annual revenue run rate with its first facility and expanding into California over the next 12-month period to enhance its output and create new opportunities.
In January, the company announced the receipt of a State Registration Certificate for its 28,000 square foot cannabis cultivation facility located in Las Vegas, Nevada. The facility will be initially equipped with 200 grow lights supporting approximately 800 cannabis plants with an initial production of 115 pounds of cannabis per month. At capacity, the facility will have 500 grow lights which is expected to generate over $12million per year in revenue.
Unlike other producers, the company standardizes its cannabis-based products through tissue-replication technology to reduce genetic drift and ensure controlled growing conditions in sterile cleanrooms. This science-based approach is coupled with strict process controls to achieve cGMP and ISO 9001:2015 compliance. These levels of safety and consistency will provide a key competitive advantage while supporting its R&D efforts.
The company hopes to eventually expand into a multi-state footprint with licenses in California, Texas, and perhaps Louisiana and Florida. This footprint will enable it to develop a nationwide brand with a consistent product and user experience. At the same time, the efforts will finance increasingly expensive clinical trials as the company advances into new FDA clinical trial stages that require larger patient populations and more advanced trials.
Not all of its compounds will be selected for FDA trials. Many will be available in dispensaries in the near future. The Company recently hired a Clinical Research Organization to assist in evaluating which of its patented compounds should be directed to either a Clinical Trial or immediate sale in dispensaries and/or licensed to cannabis companies in other states.
Looking Ahead
The cannabis industry could reach $50 billion in size by 2026, according to Cowen & Co., and GB Sciences Inc. (OTCQB: GBLX) is uniquely positioned to capitalize on the market with its revenue-generating cultivation operations and its long-term biopharmaceutical play. Investors may want to take a closer look at the stock given the many upcoming catalysts and the reasonable market capitalization of just over $30 million.
For more information, visit the company’s website or CannabisFN’s company profile.
http://www.cannabisfn.com/gb-sciences-moves-closer-clinical-trials/